ClinicalTrials.gg
RecruitingNCT06902805RHIBOTIIUpdated Apr 3, 2026

Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.

A Phase 2/3 interventional study of OnabotulinumtoxinA and Normal saline (placebo) in Base-of-thumb Osteoarthritis and Osteoarthritis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, 1 of them phase 3. Osteoarthritis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
5th of 12
120 · median 112
Started
2025
the only one that year
Phase 2/3
2 of 13
1 open now
Registered
12th of 13
by date

Among the 13 studies in Osteoarthritis by Assistance Publique - Hôpitaux de Paris, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 12th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

4 of the 13 studies in Osteoarthritis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The main objective of this study will be to compare the effects of 2 intra-articular injections of onabotulinumtoxinA with those of 1 intra-articular injection of onabotulinumtoxinA and 1 of normal saline and those of 2 intra-articular injections of normal saline on base-of-thumb pain at 6 months after the first injection.

Read the detailed description

The base of the thumb is a frequent location of osteoarthritis. Base-of-thumb osteoarthritis affects middle-aged and older individuals and results in base-of-thumb pain and limitations in hand-specific activities. For the medium and long term, evidence suggests that splinting could reduce pain and improve hand function. For the short term, a combination of conservative treatments is recommended, with small-to-moderate treatment effect. However, use of intra-articular treatments (e.g., glucocorticoids and hyaluronan) for the short and medium term is currently debated. Use of intra-articular botulinum toxin A injection as a pain modulator in joint diseases has recently raised interest. Botulinum toxin A is a neurotoxin produced by Clostridium botulinum that inhibits acetylcholine release into the synaptic cleft in cholinergic nerve terminals. Additionally, treatment with botulinum toxin A showed intrinsic antinociceptive effects in various animal models of joint diseases.

In a pilot single-centred randomized controlled trial of 60 participants with painful base-of-thumb osteoarthritis, the investigators compared the effects of a single intra-articular injection of onabotulinumtoxinA (Botox® ) with those of a single intra-articular injection of normal saline on base-of-thumb pain, and found a significant reduction in pain.

Several perspectives raised from this pilot study. Like in the treatment of spasticity, repeated courses of intra-articular injections onabotulinumtoxinA may be necessary to obtain sustained analgesic effects over time. A replication of these findings in a multicentred setting, analysis of cost-effectiveness and description of safety at longer term are also needed before the official recommendation of this treatment. In RHIBOT II, the investigators hypothesize that 2 ultrasound-guided intra-articular injections of onabotulinumtoxinA, as an add-on therapy to custom-made rigid splinting, could reduce base-of-thumb pain at 6 months after the first injection.

03

Conditions studied

  • Base-of-thumb Osteoarthritis
  • Osteoarthritis

Browse trials for

Keywords

  • base-of-thumb osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Individuals aged at least 18 years;

      • Pain intensity of at least 30 on a self-administered 11-point pain numeric rating scale (0: no pain to 100: maximal pain);
      • Pain involving the base of the thumb;
      • X-ray evidence of trapezometacarpial osteoarthritis with at least two of the following items involving the trapezometacarpial joint: osteophytes, joint space narrowing, subchondral bone sclerosis, or subchondral cysts;
      • 1990 ACR classification criteria for hand osteoarthritis adapted to trapezometacarpial osteoarthritis.
      • Patient able to give written prior to participation in the study
      • Affiliation with a mode of social security (profit or being entitled).
      • Negative pregnancy test in women of

Exclusion criteria

Exclusion Criteria:

    • Secondary osteoarthritis;

      • History of thumb surgery, inflammatory or crystal-associated rheumatic disease, or epilepsy;
      • Uncontrolled dysphagia, pneumonia, cardiovascular diseases, or clinical or subclinical signs of neuromuscular transmission disorders;
      • to onabotulinumtoxinA;
      • Neurological disorders involving the hands other than carpal tunnel syndrome;
      • Collagen disorders involving the hands;
      • Osteoarthritis predominating at the scaphotrapezial joint on x-ray;
      • Bilateral trapezometacarpial osteoarthritis without a predominant painful side;
      • Hand or wrist trauma for up to 2 months;
      • Intra-articular treatments for up to 2 months;
      • Use of IM, IV or oral for up to 2 months.
      • Protected adults (including individual under guardianship by court order)
      • Pregnant women and lactation; lack of for women of
      • Patient participating in another therapeutic study
      • Patient unable to speak and read french
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    2 intra-articular injections of onabotulinumtoxinA

    Drug: OnabotulinumtoxinA

  • Experimental
    1 intra-articular injection of onabotulinumtoxinA and 1 of normal saline

    Drug: OnabotulinumtoxinA · Drug: Normal saline (placebo)

  • Placebo comparator
    2 intra-articular injections of normal saline

    Drug: Normal saline (placebo)

Interventions

06

What researchers measure

Primary outcomes

  1. Base-of-thumb pain on a self-administered 11-point numeric rating scale

    French version of the self-administered base-of-thumb pain numeric rating scale (0: no pain to 100: maximal pain)

    Time frame: 6 months

Secondary outcomes

  1. Base-of-thumb pain on a self-administered 11-point numeric rating scale

    French version of the self-administered base-of-thumb pain numeric rating scale (0: no pain to 100: maximal pain)

    Time frame: 1 and 12 months

  2. Hand-specific activity limitations on the self-administered Cochin Hand Function Scale

    mean change from baseline in hand-specific activity limitations in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0: no limitations to 90: maximal limitations) at 6 and 12 months

    Time frame: 6 and 12 months

  3. patient global assessment on a self-administered 11-point numeric rating scale

    mean change from baseline in patient global assessment on a self-administered 11-point numeric rating scale (0: worst possible condition to 100: best possible condition) at 6 and 12 months

    Time frame: 6 and 12 months

  4. health-related quality of life on the self-administered EQ-5D-5L questionnaire

    mean change from baseline in health-related quality of life on the self-administered EQ-5D-5L questionnaire (0: death, 1: best quality of life) at 6 and 12 months

    Time frame: 6 and 12 months

  5. Osteoarthritis Research Society International-Outcome Measures in Rheumatology response

    Osteoarthritis Research Society International-Outcome Measures in Rheumatology response (Response / No response)

    Time frame: 6 and 12 months

  6. estimated total costs and incremental cost-utility ratio

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Assistance Publique - Hôpitaux de Paris, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis du Pr François Rannou, Hôpital Cochin
    Paris, Île-de-France Region 75014, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
Dec 3, 2025
Primary completionEst.
May 2027
CompletionEst.
Nov 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06902805
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Dec 3, 2025
Primary completion
May 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Christelle NGUYEN, MD, PhD
Contact
christelle.nguyen2@aphp.fr
01 58 41 29 45 ext. +33
Laetitia PEAUDECERF, PhD
Contact
laetitia.peaudecerf@aphp.fr
01 58 41 12 13 ext. +33
Christelle NGUYEN, MD,PhD
principal investigator · Organizational Affiliation: Université Paris Cité, Faculté de Santé | UFR de Médecine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion